Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone281-863-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90.33 million
Profitability
Miscellaneous
Employees174
OptionableOptionable
Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.07. The biopharmaceutical company earned $6.90 million during the quarter, compared to analysts' expectations of $12.56 million. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The company's quarterly revenue was down 74.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) earnings per share. View Lexicon Pharmaceuticals' Earnings History.
When is Lexicon Pharmaceuticals' next earnings date?
What price target have analysts set for LXRX?
7 analysts have issued twelve-month price objectives for Lexicon Pharmaceuticals' shares. Their predictions range from $10.00 to $42.00. On average, they anticipate Lexicon Pharmaceuticals' stock price to reach $25.25 in the next year. This suggests a possible upside of 323.7% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.
What is the consensus analysts' recommendation for Lexicon Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.
What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (1/18/2019)
- 2. Needham & Company LLC analysts commented, "Lexicon presented additional data from sotagliflozin Phase 3 program in at ADA mtg and published full 52wk data from both inTANDEM1 and inTANDEM2 trials. We spoke w/ mgmt for an update. Overall sotagliflozin safety/ efficacy profile is unch and we continue to believe the drug will have a role in T1D treatment. Additional data from dapagliflozin program in T1D were also presented (AstraZeneca/ BMS). Sotagliflozin may have modest benefits as a dual SGLT1/2 inhibitor over single SGLT2 inhibition, but it is still a challenge to compare the drugs across different trials. Maintain HOLD due to slow Xermelo launch and our expectation that Phase 3 T2D next year will help clarify potential overall advantages of sotagliflozin over SGLT2 inhibitors." (6/25/2018)
Has Lexicon Pharmaceuticals been receiving favorable news coverage?
Media stories about LXRX stock have trended extremely positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a coverage optimism score of 4.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Innoviva (INVA), Endocyte (ECYT), AnaptysBio (ANAB), Xencor (XNCR) and Insmed (INSM).
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Mr. Lonnel Coats, Pres, CEO & Director (Age 54)
- Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)
- Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)
- Dr. Praveen Tyle, Exec. VP of R&D (Age 59)
- Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60)
Who are Lexicon Pharmaceuticals' major shareholders?
Lexicon Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fox Run Management L.L.C. (0.02%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.
Which major investors are selling Lexicon Pharmaceuticals stock?
How do I buy shares of Lexicon Pharmaceuticals?
Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
One share of LXRX stock can currently be purchased for approximately $5.96.
How big of a company is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals has a market capitalization of $631.31 million and generates $90.33 million in revenue each year. The biopharmaceutical company earns $-129,050,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe.
What is Lexicon Pharmaceuticals' official website?
How can I contact Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.
MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
